Oncomed Pharma (OMED) 10.26 $OMED
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
GlobeNewswire - Thu Sep 01, 7:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of patient enrollment of 207 patients in the randomized Phase 2 "YOSEMITE" clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of first-line metastatic pancreatic cancer. Topline results are expected in the first half of 2017.
OMED: 10.26 (+0.27)
OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Wed Aug 31, 3:10PM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
OMED: 10.26 (+0.27), WFC: 50.43 (-0.37)
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer
GlobeNewswire - Tue Aug 30, 7:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer (SCLC). The PINNACLE study enrolled 145 patients with extensive-stage SCLC who had not received prior treatment. Topline data from the Phase 2 trial are expected to be reported at the end of 2016 or in early 2017.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
GlobeNewswire - Tue Aug 23, 3:02PM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a public offering price of $10.00 per share, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock. All shares in the offering were sold by OncoMed, with gross proceeds to OncoMed of approximately $63.3 million and net proceeds of approximately $59.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
OMED: 10.26 (+0.27), WFC: 50.43 (-0.37)
OncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Aug 18, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $10.00 per share. Net proceeds to OncoMed from this offering are expected to be approximately $51.4 million after underwriting discounts and commissions and estimated offering expenses.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Aug 17, 3:07PM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by OncoMed. In addition, OncoMed intends to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:07PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals to Report Financial Results for the Second Quarter 2016 on Tuesday, August 9, 2016
GlobeNewswire - Wed Aug 03, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell ("anti-CSC"
and immuno-oncology product candidates, will announce financial results for the quarter ended June 30, 2016 on Tuesday, August 9, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review second quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 10.26 (+0.27)
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 10.26 (+0.27)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 43.17 (+0.34), OMED: 10.26 (+0.27), LGND: 107.04 (+3.73), ANIK: 47.94 (+0.70)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 10.26 (+0.27), AZN: 32.60 (-0.21), BXLT: 46.02 (-0.18), NKTR: 18.11 (+0.26)
Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 43.17 (+0.34), OMED: 10.26 (+0.27), ANIP: 61.42 (+1.68), ILMN: 168.56 (+0.22)
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 10.26 (+0.27)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 12.23 (+0.06), OMED: 10.26 (+0.27), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CELGZ: 1.13 (-0.03)
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 10.26 (+0.27)
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 10.26 (+0.27)
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 10.26 (+0.27)
Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
GlobeNewswire - Thu Sep 01, 7:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of patient enrollment of 207 patients in the randomized Phase 2 "YOSEMITE" clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of first-line metastatic pancreatic cancer. Topline results are expected in the first half of 2017.
OMED: 10.26 (+0.27)
OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Wed Aug 31, 3:10PM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
OMED: 10.26 (+0.27), WFC: 50.43 (-0.37)
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer
GlobeNewswire - Tue Aug 30, 7:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer (SCLC). The PINNACLE study enrolled 145 patients with extensive-stage SCLC who had not received prior treatment. Topline data from the Phase 2 trial are expected to be reported at the end of 2016 or in early 2017.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
GlobeNewswire - Tue Aug 23, 3:02PM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a public offering price of $10.00 per share, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock. All shares in the offering were sold by OncoMed, with gross proceeds to OncoMed of approximately $63.3 million and net proceeds of approximately $59.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
OMED: 10.26 (+0.27), WFC: 50.43 (-0.37)
OncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Aug 18, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $10.00 per share. Net proceeds to OncoMed from this offering are expected to be approximately $51.4 million after underwriting discounts and commissions and estimated offering expenses.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Aug 17, 3:07PM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by OncoMed. In addition, OncoMed intends to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:07PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals to Report Financial Results for the Second Quarter 2016 on Tuesday, August 9, 2016
GlobeNewswire - Wed Aug 03, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell ("anti-CSC"
and immuno-oncology product candidates, will announce financial results for the quarter ended June 30, 2016 on Tuesday, August 9, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review second quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT). OMED: 10.26 (+0.27)
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 10.26 (+0.27)
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 10.26 (+0.27)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 43.17 (+0.34), OMED: 10.26 (+0.27), LGND: 107.04 (+3.73), ANIK: 47.94 (+0.70)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 10.26 (+0.27), AZN: 32.60 (-0.21), BXLT: 46.02 (-0.18), NKTR: 18.11 (+0.26)
Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 43.17 (+0.34), OMED: 10.26 (+0.27), ANIP: 61.42 (+1.68), ILMN: 168.56 (+0.22)
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 10.26 (+0.27)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 12.23 (+0.06), OMED: 10.26 (+0.27), GSK: 42.98 (-0.48), BMY: 56.76 (-0.63), CELGZ: 1.13 (-0.03)
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 10.26 (+0.27)
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 10.26 (+0.27)
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 10.26 (+0.27)
Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 10.26 (+0.27)
